Detail akcie Cytokinetics online

Business Summary: Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cytokinetics, Inc. revenues increased from $1.5M to $70.3M. Net loss increased 37% to $601.9M. Revenues reflect Cytokinetics segment increase from $463K to $70.3M. Higher net loss reflects Cytokinetics segment loss increase from $140.8M to $433.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$4.00 to -$5.04.